Investigational drug for treating metastatic pancreatic cancer

Inclusion Criteria

• Have pathologically diagnosed locally advanced or metastatic pancreatic adenocarcinoma (mPDAC)
• Be willing to submit an archived or fresh tumor specimen for central testing
• Have normal organ function
• Be over the age of 18 years old

Exclusion Criteria

• Have a history of another primary malignancy (non-melanoma skin cancers are eligible)
• Have received systemic therapy for metastatic pancreatic adenocarcinoma.
• Have previously received any immune-mediated therapy
• Have central nervous system metastasis
• Have a BRCA or sensitizing mutation for pancreatic adenocarcinoma
• Have a history of thromboembolic events (blood clots)
• Have a history of solid organ transplantation
• Have a history of primary immunodeficiency
• Have an ongoing or active infection or uncontrolled illness
• Have an autoimmune disorder

Additional Info

• This investigational drug is a first-in class-humanized monoclonal-antibody that binds with leukemia inhibitory factor. Anti-LIF's have the potential to aid standard-of-care chemotherapy to overcome resistance to chemotherapy and work alongside checkpoint inhibitors to achieve an antitumor response. Study participation will last until disease progression or unacceptable toxicity.
• All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion)
• Search NCT04999969 at https://clinicaltrials.gov website for more information.